Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CATX NASDAQ:EMBC NASDAQ:INMD NASDAQ:IRMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCATXPerspective Therapeutics$3.46-2.3%$3.75$1.60▼$16.31$256.95M1.2926,789 shs2.01 million shsEMBCEmbecta$14.96+3.2%$11.89$9.20▼$21.48$874.94M1.12631,380 shs618,453 shsINMDInMode$14.98+4.0%$14.51$13.14▼$19.85$946.87M2932,803 shs996,099 shsIRMDiRadimed$71.99-0.2%$64.97$44.58▼$74.00$915.35M1.0245,894 shs22,289 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCATXPerspective Therapeutics-2.26%+2.98%-9.42%+4.22%-76.90%EMBCEmbecta+3.24%+3.31%+51.57%+52.81%-9.00%INMDInMode+3.96%+0.27%+7.15%+5.79%-2.92%IRMDiRadimed-0.21%-0.62%+2.37%+18.99%+54.72%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCATXPerspective Therapeutics$3.46-2.3%$3.75$1.60▼$16.31$256.95M1.2926,789 shs2.01 million shsEMBCEmbecta$14.96+3.2%$11.89$9.20▼$21.48$874.94M1.12631,380 shs618,453 shsINMDInMode$14.98+4.0%$14.51$13.14▼$19.85$946.87M2932,803 shs996,099 shsIRMDiRadimed$71.99-0.2%$64.97$44.58▼$74.00$915.35M1.0245,894 shs22,289 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCATXPerspective Therapeutics-2.26%+2.98%-9.42%+4.22%-76.90%EMBCEmbecta+3.24%+3.31%+51.57%+52.81%-9.00%INMDInMode+3.96%+0.27%+7.15%+5.79%-2.92%IRMDiRadimed-0.21%-0.62%+2.37%+18.99%+54.72%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCATXPerspective Therapeutics 3.18Buy$12.56262.88% UpsideEMBCEmbecta 2.75Moderate Buy$19.0027.01% UpsideINMDInMode 2.13Hold$18.0420.44% UpsideIRMDiRadimed 3.00Buy$72.000.01% UpsideCurrent Analyst Ratings BreakdownLatest CATX, INMD, IRMD, and EMBC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/26/2025EMBCEmbectaZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy7/30/2025INMDInModeNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold7/30/2025INMDInModeBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$24.00 ➝ $21.007/16/2025EMBCEmbectaMizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$13.00 ➝ $12.007/12/2025CATXPerspective TherapeuticsLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy7/11/2025INMDInModeCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold$15.006/23/2025CATXPerspective TherapeuticsB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.00 ➝ $12.006/23/2025CATXPerspective TherapeuticsWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$11.00(Data available from 9/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCATXPerspective TherapeuticsN/AN/AN/AN/A$2.67 per shareN/AEMBCEmbecta$1.12B0.78$3.34 per share4.48($12.80) per share-1.17INMDInMode$394.82M2.40$1.82 per share8.21$10.12 per share1.48IRMDiRadimed$73.24M12.50$1.58 per share45.50$6.85 per share10.51Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCATXPerspective Therapeutics-$46.51MN/A0.00N/AN/A-4,096.66%-27.40%-23.16%11/11/2025 (Estimated)EMBCEmbecta$78.30M$1.4310.464.870.837.58%-23.40%14.46%11/25/2025 (Estimated)INMDInMode$181.27M$2.476.068.23N/A44.50%18.38%16.35%10/29/2025 (Estimated)IRMDiRadimed$19.23M$1.6244.4436.00N/A26.61%23.30%20.62%10/30/2025 (Estimated)Latest CATX, INMD, IRMD, and EMBC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/8/2025Q3 2025EMBCEmbecta$0.7720$1.12+$0.3480$0.78$278.15 million$295.50 million7/30/2025Q2 2025INMDInMode$0.50$0.47-$0.03$0.42$98.45 million$95.60 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCATXPerspective TherapeuticsN/AN/AN/AN/AN/AEMBCEmbecta$0.604.01%N/A41.96%N/AINMDInModeN/AN/AN/AN/AN/AIRMDiRadimed$0.680.94%N/A41.98%1 YearsLatest CATX, INMD, IRMD, and EMBC DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date8/6/2025EMBCEmbectaquarterly$0.154.14%8/29/20258/29/20259/15/20257/31/2025IRMDiRadimedquarterly$0.171.13%8/18/20258/18/20258/28/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCATXPerspective TherapeuticsN/A9.609.60EMBCEmbectaN/A2.471.78INMDInModeN/A9.608.58IRMDiRadimedN/A8.787.51Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCATXPerspective Therapeutics54.66%EMBCEmbecta93.83%INMDInMode68.04%IRMDiRadimed92.34%Insider OwnershipCompanyInsider OwnershipCATXPerspective Therapeutics3.72%EMBCEmbecta0.42%INMDInMode6.92%IRMDiRadimed36.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCATXPerspective Therapeutics7074.26 million65.21 millionOptionableEMBCEmbecta2,10058.49 million58.24 millionOptionableINMDInMode48063.21 million58.84 millionOptionableIRMDiRadimed11012.72 million8.04 millionOptionableCATX, INMD, IRMD, and EMBC HeadlinesRecent News About These CompaniesDoes IRADIMED (NASDAQ:IRMD) Deserve A Spot On Your Watchlist?September 6 at 4:48 PM | finance.yahoo.comIradimed Appoints Joe Kiani as New DirectorSeptember 3 at 4:48 PM | msn.comIRADIMED CORPORATION Announces Board Transition: Anthony Vuoto Retires, Joe Kiani Appointed as ...September 2, 2025 | bakersfield.comBIRADIMED CORPORATION Announces Board Transition: Anthony Vuoto Retires, Joe Kiani Appointed as New DirectorSeptember 2, 2025 | finance.yahoo.comNuveen LLC Buys New Position in iRadimed Corporation $IRMDSeptember 2, 2025 | marketbeat.comContrasting iRadimed (NASDAQ:IRMD) and TransMedics Group (NASDAQ:TMDX)September 1, 2025 | americanbankingnews.comAlphaQuest LLC Purchases 3,936 Shares of iRadimed Corporation $IRMDAugust 30, 2025 | marketbeat.comVanguard Group Inc. Has $29.10 Million Holdings in iRadimed Corporation $IRMDAugust 30, 2025 | marketbeat.comiRadimed (NASDAQ:IRMD) Reaches New 12-Month High - Time to Buy?August 29, 2025 | marketbeat.comIRADIMED CORPORATION to Participate in the 2025 Wells Fargo Healthcare ConferenceAugust 26, 2025 | globenewswire.comAlgert Global LLC Reduces Holdings in iRadimed Corporation $IRMDAugust 25, 2025 | marketbeat.comiRadimed Corporation $IRMD Shares Sold by Russell Investments Group Ltd.August 22, 2025 | marketbeat.comIRadimed: Continued Value Unlock With Extensive Reinvestment RunwayAugust 21, 2025 | seekingalpha.com48,126 Shares in iRadimed Corporation (NASDAQ:IRMD) Acquired by Roubaix Capital LLCAugust 19, 2025 | marketbeat.comLiontrust Investment Partners LLP Has $2.12 Million Position in iRadimed Corporation (NASDAQ:IRMD)August 18, 2025 | marketbeat.comSei Investments Co. Acquires 4,874 Shares of iRadimed Corporation (NASDAQ:IRMD)August 18, 2025 | marketbeat.comIradimed Corp’s Earnings Call Highlights Record GrowthAugust 15, 2025 | theglobeandmail.comiRadimed (NASDAQ:IRMD) Hits New 1-Year High - Here's WhyAugust 14, 2025 | marketbeat.comRoth MKM Remains a Buy on Iradimed (IRMD)August 14, 2025 | theglobeandmail.comThree Days Left Until IRADIMED CORPORATION (NASDAQ:IRMD) Trades Ex-DividendAugust 14, 2025 | finance.yahoo.comAre Robust Financials Driving The Recent Rally In IRADIMED CORPORATION's (NASDAQ:IRMD) Stock?August 12, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCATX, INMD, IRMD, and EMBC Company DescriptionsPerspective Therapeutics NYSE:CATX$3.46 -0.08 (-2.26%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$3.53 +0.07 (+2.02%) As of 09/5/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.Embecta NASDAQ:EMBC$14.96 +0.47 (+3.24%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$14.97 +0.01 (+0.07%) As of 09/5/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.InMode NASDAQ:INMD$14.98 +0.57 (+3.96%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$14.86 -0.12 (-0.79%) As of 09/5/2025 07:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokneam, Israel.iRadimed NASDAQ:IRMD$71.99 -0.15 (-0.21%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$72.06 +0.07 (+0.09%) As of 09/5/2025 04:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Salesforce Stumbles, But Investors Eye a Major Comeback Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
